Is bosutinib/bosutinib included in medical insurance?

Bosutinib/Bosutinib is a targeted drug for Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Its main mechanism of action is to prevent the growth and reproduction of cancer cells by inhibiting the activity of tyrosine kinases. The drug is indicated for patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia, as well as patients aged 1 year and older with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase, accelerated phase or blast phase, especially those who have developed resistance or intolerance to previous treatments.

Bosutinib has good efficacy, especially in the treatment of patients who have developed resistance to other tyrosine kinase inhibitors (such as imatinib, etc.). This feature makes bosutinib one of the important choices in the treatment of chronic myelogenous leukemia. In addition, bosutinib has shown a relatively low incidence of side effects in clinical trials, which provides assurance for its use in long-term treatment.

However, the original drug of bosutinib has not yet been launched in the Chinese market, so it cannot be included in medical insurance. This situation results in patients who need to use the drug facing a high financial burden, because they need to bear the full cost of the drug themselves, which is a big stress for many patients. Although some generic drugs are under development in China, they still need to undergo strict clinical verification in terms of quality and efficacy to ensure that patients can be provided with safe and effective treatment options.

As China's approval process for innovative drugs continues to be optimized, bosutinib may gain market access in the future, thereby providing treatment opportunities for more patients. At the same time, the possibility of drugs entering medical insurance is also increasing, which will significantly reduce patients’ medication costs and improve their treatment experience.

Reference materials:https://go.drugbank.com/drugs/DB06616